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Objective: To evaluate the beneﬁts of antibiotic-impregnated inﬂatable penile prosthesis (IPP; Inhib-
iZone®) in patients at high risk of infection in Taiwan.
Materials and methods: From 2004 to 2008, 39 patients diagnosed with uncorrectable erectile dysfunction
received an IPP implantation at our hospitals. Based on the underlying diseases, the patients were divided
into groups. The results of the two study groups were compared with a control group, which received a
conventional IPP implantation. The control group was also divided into two groups based on underlying
diseases, similar to that of the study groups. Single-tailed Student t test was performed to determine the
differencebetweeneachgroupandtocompare thedataof ourpatientswithourpreviouslypublished results.
Results: Surgical outcome analysis showed that the postoperative infection rate is lower in the InhibiZone
group (2.6% overall, 5.6% in the high-risk group, and 8.3% in revision surgeries) compared with the con-
ventional (control) IPP group (9.6% overall, 25% in the high-risk group, and 33.3% in revision surgeries). The
postoperative infection rate is obviously higher in the high-risk group, irrespective of whether the patient
received InhibiZone prostheses or the conventional ones. Furthermore, for patients prone to a high risk of
prosthesis infection, InhibiZone penile prosthesis was used instead of the conventional prosthesis, and this
was found to reduce the infection rate (from25% to 5.6%); furthermore, the overall infection rate (from9.6%
to 2.6%) was found to be reduced in the group that received InhibiZone prostheses and in patients with
common etiologies (from 5% to 0%), both of which were prominent and statistically signiﬁcant.
Conclusion: An antibiotic-impregnated IPP (InhibiZone®) deﬁnitely increases the success rate of reim-
plantation surgery, and can be indicated for patients at a high risk of postoperative infection.
Copyright © 2016, Taiwan Urological Association. Published by Elsevier Taiwan LLC. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Erectile dysfunction (ED) is a highly prevalent disease, with
reports indicating that it is much more prevalent than previously
thought. According to the Massachusetts Male Aging Study, 52% of
US men aged> 40 years have some degree of ED.1 Similar results
were also observed in an epidemiological study in Taiwan2 and in
other Asian countries.3 Among the recent advances in ED treat-
ment, many less-invasive alternatives, especially oral medications
[i.e., phosphodiesterase type 5 (PDE-5) inhibitors], have seemingly
replaced the previously popular modality of penile implant surgery.eelung Hospital, Ministry of
i District, Keelung City 20147,
-L. Chang).
ociation. Published by Elsevier TaHowever, penile prosthesis implantation still has its place as a
deﬁnite and permanent therapy for patients with uncorrectable ED.
Two major complications following penile prosthesis implan-
tation have been widely discussed and are thought to limit its
popularity of being a more acceptable treatment option for patients
with ED. The ﬁrst one is mechanical dysfunction, where the penile
prostheses are not as durable as patients expected.4 However,
recent improvements in prosthesis designs have increased the
reliability of inﬂatable penile prostheses (IPPs).5 The second major
complication is postoperative infection. Prosthetic infection may
cause intolerable pain to patients, local abscess formation, and even
sepsis. In some cases, it may lead to ﬁbrosis of corpus cavernosum
tissue, eventually forcing the removal of the penile prosthesis. In a
previous study,6 the success rate of further reimplantation in pa-
tients with smaller corporeal diameter was only 68.4%. Populations
at high risk of prosthesis infection include those with diabetesiwan LLC. This is an open access article under the CC BY-NC-ND license (http://
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and repeated penile prosthesis implantation, especially due to
previous infection.8
To prevent prosthetic infection and enhance the success rate of
reimplantation surgery, several new designs of penile prosthesis
have been developed in recent years.9 In 2000, the AmericanMedical
System (AMS) introduced an IPP, AMS 700 CXR with InhibiZone®, to
prevent bacterial adhesion during surgery.10 The surface of AMS
InhibiZone® is coated with a combination of rifampicin and mino-
cycline, which are effective against themost commonGram-positive
bacteria. The AMS InhibiZone® had proven to be more effective than
prostheses without an antibiotic coating for prevention of
prosthesis-related infection in penile prosthesis surgery.10,11 We
started our surgical implantation of this antibiotic-impregnated IPP
as early as it appearedon the Taiwanesemarket.However, the license
renewal of this product had been suspended by the Taiwanese Food
andDrug Administration formany years. In this study, we performed
a long-term evaluation of 39 patients with regard to the beneﬁt of
using this antibiotic-impregnated IPP. Our study results are useful for
treating Asian patients with uncorrectable ED.
2. Materials and Methods
From 2004 to 2008, 39 patients diagnosed with uncorrectable
ED received an IPP (AMS 700 CXR, InhibiZone®, American Medical
System, Minnetonka, MN, USA) implantation at our hospitals. Their
previous medical histories concerning the etiology and therapy of
ED were recorded. The underlying diseases that caused ED in these
patients are listed in Table 1. To evaluate the effect of implantation
of the antibiotic-coated penile prosthesis on improved surgical
outcomes, we divided the underlying diseases of our study popu-
lation into two groups. One group included patients with the
common etiologies of ED such as vasculogenic causes, pure venous
leakage, and Peyronie’s disease. The other group included patients
with etiologies that have a high risk of causing perioperative and
postoperative infections, including patients with DM and those
who had received revision or reimplantation surgery.We compared
these groups with a control group, which included 52 patients who
received a conventional IPP implantation from 1985 to 1996.6 The
control group was also divided into two groups based on under-
lying diseases, similar to that of the study groups.
All patients were instructed about the advantages and disad-
vantages of each type of penile prosthesis available in the market.
They were all well aware of the newly designed, antibiotic-coated
IPP (InhibiZone®), and thought that it may be the best option to
meet their expectations. The ﬁnal decisionwas made by the patient
and his partner. They also provided written informed consent for
the surgery and postoperative follow up.Table 1
Underlying diseases of the patients receiving InhibiZone (antibiotic-coated penile
prosthesis) and conventional IPP (nonantibiotic-coated penile prosthesis)
implantation.
InhibiZone group
(N¼ 39)
Conventional IPP group
(N¼ 52)
Common etiologies 21/39 (54%) 40/52 (77%)
Vasculogenic causes 15 29
Pure venous leakage 2 6
Peyronie’s disease 0 4
After radical surgery 4 1
High risk 18/39 (46%) 12/52 (23%)
Revision 12 a 3
Diabetes mellitus 7 a 9
Spinal cord injury 1 0
IPP¼ inﬂatable penile prosthesis.
a There are two patients with diabetes mellitus and their surgery was also
revision surgery.Surgical procedure was performed through a penoscrotal inci-
sion to approach the scrotum and corpus cavernosum. About 30
minutes before the operation, all patients received cefazolin (1 g
administered intravenously) as the prophylactic antibiotic. During
the revision surgery, extensive irrigation with 5 L of a mixed solu-
tion of 50% povidone iodine and 50% hydrogen peroxide, and
vancomycin lavage was performed after removing the old pros-
thesis. Gentamycin lavage is used for every patient receiving
prosthesis implantation.
The short-term evaluation included clinical observation during
the perioperative and immediate postoperative periods. All adverse
events during the operation, especially postoperative deformity or
mechanical failure, were recorded. Infections are the most
commonly encountered threat following penile prosthesis im-
plantation. Any of the following ﬁndings in a local wound is
considered to be a sign of infection: hematoma, edematous
swelling, any kind of discharge, persistent pain, and delayed heal-
ing. Immediate postoperative infection may eventually result in a
revision procedure or prosthesis removal. Postoperative follow up
was performed weekly for up to 1 month or a little longer, when
patients were able to manipulate the penile prosthesis by them-
selves without any discomfort.
Long-term follow upwas done by telephone interview for up to 5
years after the operation. For this purpose, we used a questionnaire
that focused on the status of the implanted penile prosthesis to
exclude any mechanical failure or other complications. Convenience
inperformingdailyactivitieswith thepenileprosthesis andsexual life
satisfaction of the patients were of greatest concern, and if needed, a
further visit would be arranged for evaluation and treatment.
2.1. Statistical analysis
Statistical analysis was performed using SAS version 8 (SAS
Institute, Cary, NC, USA). Single-tailed Student t test was performed
to determine the difference between each group and to compare
data of our patients with our previously published results (Table 2).
The signiﬁcance level was set at p< 0.05.
3. Results
A total of 39 patients (age 34e82 years, mean 65.2 years)
received InhibiZone® penile prosthesis implantation, with a follow-
up period between 2 months and 45 months (mean 16 months); 18
(46%) of these patients belonged to the high-risk group, and 12 (31%)
received prosthesis revision surgeries. The distribution of patients in
this study was different from the conventional IPP group (control
group),6 where among the 52 patients studied, only 12 (23%) pa-
tients belonged to the high-risk group, and nine (17%) received
revision surgeries (Table 1). This difference is because the Inhib-
iZone® penile prosthesis had only recently been launched, that is,
after effective oral agents for erection dysfunction (e.g., PDE-5 in-
hibitors) appeared on the market. Surgery was performed only in
patients with ED whose conditions could not be treated by conser-
vative treatment. Therefore, these patients hadmore underlying risk
factors that can cause prosthesis surgical infection at a later stage.
Surgical outcome analysis showed that the postoperative
infection rate is lower in the InhibiZone group (2.6% overall, 5.6% in
the high-risk group, and 8.3% in revision surgeries) compared with
the conventional (control) IPP group (9.6% overall, 25% in the high-
risk group, and 33.3% in revision surgeries; Table 2). The post-
operative infection rate is obviously higher in the high-risk group,
irrespective of whether the patient received InhibiZone prostheses
or the conventional ones. Furthermore, for patients prone to a high
risk of prosthesis infection, InhibiZone penile prosthesis was used
instead of the conventional prosthesis, and this was found to
Table 2
Comparison of the surgical outcomes between the InhibiZone and conventional IPP implantation groups.
Overall, n/N (%) High risk, n/N (%) As revision surgery, n/N (%) p
Infection 0.037 *
InhibiZone group 1/39 (2.6) 1/18 (5.6) 1/12 (8.3)
Conventional IPP group 5/52 (9.6) 3/12 (25.0) 3/9 (33.3)
Mechanical failure 0.399
InhibiZone group 1/39 (2.6) 1/18 (5.6) 0/12 (0.0)
Conventional IPP group 6/52 (11.5) 0/12 (0.0) 0/9 (0.0)
* p< 0.05.
IPP¼ inﬂatable penile prosthesis.
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overall infection rate (from 9.6% to 2.6%) was found to be reduced in
the group that received InhibiZone prostheses and in patients with
common etiologies (from 5% to 0%), both of which were prominent
and statistically signiﬁcant.
In the conventional IPP group, prosthesis removal was per-
formed in 11 cases (due to infectious problems in 5 cases, and
mechanical problems in 6 cases). None of the patients who received
the antibiotic-coated penile prosthesis, InhibiZone®, suffered in-
fections following implantation. Even in the revision surgeries,11 of
12 (91.7%) patients had excellent surgical outcome. To date, only
one case each of mechanical failure and postoperative infection
occurred in the patient group with high-risk factors. The post-
operative infection occurred in a diabetic patient after radical sur-
gery and chemotherapy for colon cancer, and had received penile
prosthesis operation six times. In this patient, infectious problems
occurred in the 16th month, and the implanted InhibiZone penile
prosthesis was eventually removed 2 months later because of un-
controllable infection.
The quality of patient’s sexual life was evaluated using a ques-
tionnaire. Patients’ overall satisfaction after IPP implantation was
89.7% (35/39); 94.9% (37/39) of the patients reported that theywere
satisﬁed with their sexual life and their intercourse frequency
increased after the implantation, with 89.7% (35/39) of the patients
experiencing orgasm during sex. As much as 94.9% (37/39) of their
partners reported satisﬁed sexual life, which is a little higher than
that reported by the patients.4. Discussion
To improve the durability of penile prostheses, overcoming the
problems of surgical infection had been a major challenge in the
past decades. Two theories were developed to explain the high
infection rate in prosthesis implantation. Studies have demon-
strated how an implanted foreign body decreases and weakens the
host immune defense systems: ﬁrst, through alteration of the
complement pathway, including eicosanoids, reactive oxygen in-
termediates, and the cytokine cascade12; and second, the prosthesis
material is likely to support bioﬁlm formation, and thus attract
bacteria. Common infectious pathogens include Staphylococcus
aureus, Pseudomonas aeruginosa, and occasionally Staphylococcus
epidermidis.13 It is difﬁcult to precisely identify when the pathogens
colonize a prosthesis. It is generally believed that pathogens infect
at the time of original implantation and colonize it later.14 Bacteria
may also come in contact with prosthetic materials through he-
matogenous and lymphatic spread.15 The organism most often
encountered on penile prostheses is S. epidermidis (35e56%) fol-
lowed by S. aureus.10 Among the early efforts to decrease
prosthesis-related infections, perioperative administration of an-
tibiotics was the most common method. Raad et al16,17 carried out
in vitro studies and showed that catheters coated with a combi-
nation of rifampicin and minocycline were most effective when
compared with other combinations. This combination of drugsshowed broad-spectrum inhibitory activity against both Gram-
positive and Gram-negative bacteria, and was particularly effec-
tive against Staphylococcus sp., the most common cause of IPP in-
fections.18 Different mechanisms of the two drugs, minocycline
inhibits protein synthesis and rifampicin inhibits DNA-dependent
RNA polymerase, may reduce the likelihood of developing bacte-
rial resistance to each individual agent.
InhibiZone® is a patented industrial antibiotic impregnation
process that incorporates both rifampicin and minocycline. The
treated surface can produce a stable elute proﬁle that can be
effective up to 14 days after the implantation. In 2004, Culley C.
Carson10 performed a retrospective study to determine the differ-
ence between InhibiZone® IPPs and original implants (i.e., un-
treated prosthesis). This study series evaluated 4205 original
implant surgeries performed between 2001 and 2003 in the United
States with a follow-up period of 12e24 months. A signiﬁcantly
decreased rate of prosthesis infection in the study group, in com-
parisonwith the control group, was observed after 60 days, 90 days,
120 days, and 180 days. Even after 366 days, a 61.7% decrease in the
infection rate was observed.10
Wilson et al19 reported a reduction in infection rate when using
antibiotic-coated IPPs. In their study, a total of 467 patients were
included and stratiﬁed into four groups. No infections developed
among the 223 virgin prosthesis implanted in nondiabetic patients.
Diabetic patients with virgin implants had a 1% infection rate. Pa-
tients who received revision surgery without washout had a 10%
infection rate. By contrast, when revision surgery was carried out
with an antiseptic washout, the infection rate dropped to 3%. A
statistically signiﬁcant reduction in the infection rate was found in
all three groups, but not in the group with revision surgery without
washout compared with their previous data.
Our present study provides further evidence that antibiotic-
impregnated IPPs can signiﬁcantly reduce the rate of surgical
infection for Oriental patients, especially those at a high risk of
infection. They either have an underlying disease, which is a pre-
disposing factor for surgical infection, commonly DM, or had un-
dergone reimplantation and revision surgeries. In the literature, the
general infection rate after revision of a penile prosthesis is 13.3%,20
which might not differ from that for patients requiring other
reconstructive surgeries. Jarow20 reported an infection rate of 21.7%
for procedures requiring reconstruction of the corpora, compared
with only 1.8% in men without previous penile surgery. Lynch
et al21 reported an even higher incidence of infection in diabetic
patients receiving an IPP in comparison with nondiabetic patients
(22% vs. 6.7%). Our previous experience also showed a high inci-
dence (25%) of postoperative infection in diabetic patients after IPP
implantation.5 Only a 68.7% success rate of reimplantation surgery
was achieved 6 months after the infected prosthesis had been
removed. Our recent experience with InhibiZone® implantation is
remarkably progressive, although one case of postoperative infec-
tion still occurred compared with none in patients without previ-
ous implantation. The infected patient had exceptionally high
multiple risk factors of DM, an immunosuppressed condition, and
Table 3
Evolution of the cylinder design from the conventional IPPs to InhibiZone.
Diameter Length
AMS 700 CX 12 mm 12 cm, 15 cm, 18 cm, 21 cm
AMS 700 CXM 9.5 mm (distal end)
10.94 mm (proximal end)
12 cm, 14 cm, 16 cm, 18 cm
AMS 700 CXR
InhibiZone
9.5 mm (distal end)
8.9 mm (proximal end)
12 cm, 14 cm, 16 cm, 18 cm
AMS¼American Medical System; IPP¼ inﬂatable penile prosthesis.
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vious experience, may have also been improved by a “salvage-and-
rescue” procedure, where copious irrigation with a vancomy-
cinegentamycin solution was performed in all affected chambers
through a rubber catheter placed in each area.22 It was reported
that this “washout” procedure increases the success rate to over
80% for early salvage reimplantation surgery. However, this might
not be indicated for patients with severe infection, insulin-
dependent DM, or an immunocompromised status, as with our
only failed case.23
The other beneﬁt of using InhibiZone® for penile prosthesis
reimplantation is that it has newly designed components. The
extremely ﬁne cylinder with maximal expansion, reinforcement of
the pump-tubing connections, tighter rear-tip extender for plug-
ging, and a new tactile pump render the reimplantation procedure
easier to perform. In our previous study, Taiwanese menwere found
to have thinner diameter of corpus cavernosum thanWesternmen5;
in 29.3% of the patients, the corporeal diameter was< 11mm, which
may not ﬁt with the previous IPPs, as these were originally designed
for Western men whose an average diameter of the corpus cav-
ernosum was 11e12 mm. Unfavorable prostheses size would result
in a prolonged operative time and increased risk of complications.
Chronic tissue ischemia due to excessive compression by the rela-
tively large prosthesis would also deteriorate the regional immunity.
Increased prosthesis infection rate and possibility of tunica albu-
ginea rupture are also possible under such a circumstance. However,
this newly designed IPP has a diameter of 9.5 mm in the distal end
and 8.9 mm in the proximal end, which seems to be a better ﬁt for
the Oriental population (Table 3). Because the surgical processes of
releasing ﬁbrotic tissues, identifying the corpus cavernosum, and
dilating the corporeal lumen to the maximal possibility are more
uneventful, these reduce the mechanical failure rate and also elim-
inate the possibilities of surgical infection, thereby making the
penile prosthesis more reliable.
Long-term follow up to evaluate the survival of the antibiotic-
impregnated penile prosthesis as well as the patientepartner
satisfaction is very promising (89.7%) in our series. The survival of
the penile prosthesis and the patientepartner satisfaction rate of
the InhibiZone® are comparable with other types of IPP currently
available in the market. These are proven to have similar reliability
in terms of clinical outcome and patient satisfaction.24 Based on our
experience, it was concluded that an antibiotic-impregnated IPP
(InhibiZone®) deﬁnitely increases the success rate of reimplanta-
tion surgery, and it is especially indicated for patients at a high risk
of postoperative infection. We believe that this penile prosthesis is
more reliable for use in severe ED cases, and can lead to better
sexual performance compared with other therapies that only
restore temporary sexual function. This concept and further
development will certainly begin a new era of penile prosthesis for
treating patients with uncorrectable ED.
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